JP2004248677A5 - - Google Patents

Download PDF

Info

Publication number
JP2004248677A5
JP2004248677A5 JP2004113481A JP2004113481A JP2004248677A5 JP 2004248677 A5 JP2004248677 A5 JP 2004248677A5 JP 2004113481 A JP2004113481 A JP 2004113481A JP 2004113481 A JP2004113481 A JP 2004113481A JP 2004248677 A5 JP2004248677 A5 JP 2004248677A5
Authority
JP
Japan
Prior art keywords
pro
ctla4
tyr
soluble ctla4
extracellular domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004113481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004248677A (ja
Filing date
Publication date
Priority claimed from US08/228,208 external-priority patent/US6090914A/en
Application filed filed Critical
Publication of JP2004248677A publication Critical patent/JP2004248677A/ja
Publication of JP2004248677A5 publication Critical patent/JP2004248677A5/ja
Pending legal-status Critical Current

Links

JP2004113481A 1994-04-15 2004-04-07 Ｃｔｌａ４分子及びｉｌ４結合分子並びにそれらの使用 Pending JP2004248677A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/228,208 US6090914A (en) 1991-06-27 1994-04-15 CTLA4/CD28Ig hybrid fusion proteins and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP7115095A Division JPH0847391A (ja) 1994-04-15 1995-04-17 Ｃｔｌａ４分子及びｉｌ４結合分子並びにそれらの使用

Publications (2)

Publication Number Publication Date
JP2004248677A JP2004248677A (ja) 2004-09-09
JP2004248677A5 true JP2004248677A5 (enExample) 2005-09-02

Family

ID=22856248

Family Applications (2)

Application Number Title Priority Date Filing Date
JP7115095A Withdrawn JPH0847391A (ja) 1994-04-15 1995-04-17 Ｃｔｌａ４分子及びｉｌ４結合分子並びにそれらの使用
JP2004113481A Pending JP2004248677A (ja) 1994-04-15 2004-04-07 Ｃｔｌａ４分子及びｉｌ４結合分子並びにそれらの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP7115095A Withdrawn JPH0847391A (ja) 1994-04-15 1995-04-17 Ｃｔｌａ４分子及びｉｌ４結合分子並びにそれらの使用

Country Status (8)

Country Link
US (1) US6090914A (enExample)
EP (2) EP1666498A3 (enExample)
JP (2) JPH0847391A (enExample)
AU (1) AU701310B2 (enExample)
CA (1) CA2146895C (enExample)
FI (2) FI951801A7 (enExample)
IL (1) IL113343A (enExample)
NO (1) NO322278B1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6084067A (en) * 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
US6824779B1 (en) * 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) * 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
AU710998B2 (en) * 1996-03-20 1999-10-07 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US20060034844A1 (en) * 1996-12-04 2006-02-16 The Regents Of The University Of California Stimulation of T cells against self antigens using CTLA-4 blocking agents
KR19980066046A (ko) * 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
AU9095498A (en) * 1997-09-19 1999-04-12 Yoshitomi Pharmaceutical Industries, Ltd. Oligopeptide compounds
EP0947582A1 (en) * 1998-03-31 1999-10-06 Innogenetics N.V. A polypeptide structure for use as a scaffold
AU6615500A (en) * 1999-07-28 2001-02-19 Genetics Institute Inc. Preventing immune-mediated abortion by inhibiting costimulation
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1165752A4 (en) * 1999-10-22 2003-02-05 Alexion Pharma Inc MODIFIED RECOMBINATION MOLECULE REGULATING HUMOR AND CELLULAR EFFECTOR FUNCTIONS OF THE IMMUNE SYSTEM
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP1294391B1 (en) 2000-06-09 2012-08-15 Bristol-Myers Squibb Company Combination of agents for inhibiting transplant rejection
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SI1935427T1 (en) 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2008200400B2 (en) * 2001-01-17 2012-06-07 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
DK1451224T3 (da) * 2001-12-04 2012-11-19 Theramab Llc Peptid eller protein, der indeholder en C´-D-sløjfe fra CD28-receptorfamilien
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
ES2384168T3 (es) 2002-04-12 2012-07-02 Medarex, Inc. Procedimientos de tratamiento usando anticuerpos CTLA-4
WO2003092624A2 (en) * 2002-05-02 2003-11-13 University Of Connecticut Health Center Use of heat shock proteins to enhance efficacy of antibody therapeutics
EP1549678A4 (en) * 2002-09-30 2006-01-18 Pfizer Prod Inc HYBRIDOMAS THAT PRODUCE HIGH CONCENTRATIONS OF ANTIBODIES TO THE HUMAN SEQUENCE
US7332303B2 (en) * 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
AU2003300276B2 (en) * 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
NZ545314A (en) * 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
KR100545720B1 (ko) * 2004-05-31 2006-01-24 메덱스젠 주식회사 당화된 면역글로불린 및 이를 포함하는 면역접합체
US7453291B2 (en) * 2004-09-09 2008-11-18 The Regents Of The University Of California Switch linearized track and hold circuit for switch linearization
SI1868635T1 (sl) * 2005-04-06 2017-07-31 Bristol-Myers Squibb Company Postopki za zdravljenje imunskih motenj, povezanih s transplantacijo presadkov s topnimi mutiranimi CTLA4 molekulami
EP2295080A3 (en) * 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
CN101325971A (zh) 2005-12-07 2008-12-17 米德列斯公司 Ctla-4抗体剂量递增方案
PL2253644T3 (pl) 2005-12-20 2014-04-30 Bristol Myers Squibb Co Kompozycje i sposoby wytwarzania kompozycji
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP1996716B1 (en) 2006-03-20 2011-05-11 The Regents of the University of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
PT2222697E (pt) 2007-11-01 2013-02-15 Perseid Therapeutics Llc Polipeptídeos imunossupressores e ácidos nucleicos
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
EP3281955A1 (en) 2008-10-02 2018-02-14 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2545073B1 (en) 2010-03-12 2015-09-30 AbbVie Biotherapeutics Inc. Ctla4 proteins and their uses
CN103153332A (zh) 2010-09-28 2013-06-12 卡尔医疗有限公司 用于治疗血液恶性肿瘤的组合物和方法
US9688740B2 (en) 2011-10-26 2017-06-27 National Cancer Center Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
WO2013062365A2 (ko) * 2011-10-26 2013-05-02 국립암센터 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
JP2025540660A (ja) * 2022-11-18 2025-12-16 ソウル大学校産学協力団 Ｃｔｌａ－４変異体及びキメラ抗原受容体を用いた二重遺伝子導入免疫細胞及びその用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA2003455C (en) * 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
EP0606217B2 (en) * 1991-06-27 2008-12-03 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
WO1994028912A1 (en) * 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Cd28 pathway immunosuppression

Similar Documents

Publication Publication Date Title
US12152060B2 (en) Interleukin-2 variants and methods of uses thereof
JP2023166395A5 (enExample)
TW201134481A (en) CTLA4 proteins and their uses
JP2021508449A5 (enExample)
JP2020521452A5 (enExample)
CN114728040A (zh) 新型白介素-2变体及其双功能融合分子
KR102247704B1 (ko) 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
JP2017527272A5 (enExample)
JP2023081303A5 (enExample)
JP2010533498A5 (enExample)
JP2006526414A5 (enExample)
JP2019507589A5 (enExample)
JP2010511388A5 (enExample)
JP2006340714A5 (enExample)
JP2012500006A5 (enExample)
JP2011509245A5 (enExample)
JP2009517006A5 (enExample)
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2012500020A5 (enExample)
RU2011101969A (ru) Антитела к человеческому интерлейкину-20
JP2021505156A5 (enExample)
RU2010136940A (ru) Антитела против альфа5-бета1 и их применение
JP2022523524A5 (enExample)
JP2007536933A5 (enExample)
CA2562764A1 (en) Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo